Innate Pharma (IPHA) Receivables - Net (2017 - 2025)
Innate Pharma's (IPHA) quarterly Receivables - Net came in at $14.7 million in Q4 2025, up 177.17% YoY from $5.3 million in Q4 2024, and down 23.41% on a QoQ basis from $19.2 million in Q2 2025.
Innate Pharma (IPHA) Receivables - Net (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Receivables - Net data on file, last reported at $14.7 million in Q4 2025.
- Quarterly Receivables - Net rose 177.17% year-over-year to $14.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.7 million (up 177.17% YoY) and the FY2025 annual result came in at $14.7 million, down 3.63% from the prior year.
- Receivables - Net slipped to $14.7 million in Q4 2025, from $19.2 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $71.1 million in Q4 2023 to a low of $5.3 million in Q4 2024.
- A 5-year average of $43.7 million and a median of $53.9 million in 2021 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2021 — Receivables - Net tumbled 99.66% — and 2025, when it soared 177.17%.
- Tracing IPHA's Receivables - Net over 5 years: stood at $55.2 million in 2021, then decreased by 3.04% to $53.5 million in 2022, then jumped by 32.94% to $71.1 million in 2023, then sank by 92.53% to $5.3 million in 2024, then jumped by 177.17% to $14.7 million in 2025.
- The last three Receivables - Net figures came in at $14.7 million (Q4 2025), $19.2 million (Q2 2025), and $5.3 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - |
| 10 | Innate Pharma | 199.79 Mn | 199.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.73 Mn |
| Dec 31, 2025 | 14.73 Mn |
| Jun 30, 2025 | 19.23 Mn |
| Jun 30, 2025 | 19.23 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Jun 30, 2024 | 36.91 Mn |
| Jun 30, 2024 | 36.91 Mn |
| Dec 31, 2023 | 71.13 Mn |
| Dec 31, 2023 | 71.13 Mn |
| Jun 30, 2023 | 61.47 Mn |
| Jun 30, 2023 | 61.47 Mn |
| Dec 31, 2022 | 53.51 Mn |
| Dec 31, 2022 | 53.51 Mn |
| Jun 30, 2022 | 65.66 Mn |
| Jun 30, 2022 | 65.66 Mn |
| Dec 31, 2021 | 55.19 Mn |
| Dec 31, 2021 | 55.19 Mn |
| Jun 30, 2021 | 54.34 Mn |
| Jun 30, 2021 | 54.34 Mn |